Modality
Gene Editing
MOA
EGFRi
Target
PCSK9
Pathway
Angiogenesis
SCLCACCWM
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
~Nov 2018
→ ~Feb 2020
Phase 3
May 2020
→ Jul 2031
Phase 3Current
NCT04356034
1,198 pts·ACC
2020-05→2031-07·Terminated
NCT05261232
1,299 pts·SCLC
2025-07→TBD·Completed
2,497 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-215.3y awayPh3 Readout· ACC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Complet…
Catalysts
Ph3 Readout
2031-07-21 · 5.3y away
ACC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04356034 | Phase 3 | ACC | Terminated | 1198 | EASI-75 |
| NCT05261232 | Phase 3 | SCLC | Completed | 1299 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |